GH Research (GHRS) to Release Earnings on Thursday

GH Research (NASDAQ:GHRS) is anticipated to announce its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.29) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, March 6, 2026 at 9:30 AM ET.

GH Research Trading Down 0.8%

Shares of NASDAQ GHRS opened at $15.29 on Wednesday. The stock has a market cap of $795.51 million, a PE ratio of -20.66 and a beta of 0.99. GH Research has a 12-month low of $7.98 and a 12-month high of $19.51. The company has a 50-day moving average of $15.02 and a 200 day moving average of $14.09.

Analysts Set New Price Targets

GHRS has been the topic of a number of recent research reports. Guggenheim reissued a “buy” rating and set a $29.00 price objective on shares of GH Research in a research note on Monday, January 5th. Canaccord Genuity Group boosted their price target on shares of GH Research from $35.00 to $39.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Weiss Ratings restated a “sell (d-)” rating on shares of GH Research in a research report on Thursday, January 22nd. HC Wainwright reduced their target price on shares of GH Research from $40.00 to $35.00 and set a “buy” rating on the stock in a research note on Monday, November 10th. Finally, Needham & Company LLC set a $29.00 price objective on GH Research in a report on Tuesday, January 6th. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.11.

Institutional Investors Weigh In On GH Research

Several large investors have recently added to or reduced their stakes in the business. Barclays PLC increased its stake in shares of GH Research by 63.4% during the fourth quarter. Barclays PLC now owns 2,118 shares of the company’s stock worth $27,000 after buying an additional 822 shares during the period. Osaic Holdings Inc. increased its stake in shares of GH Research by 63.6% during the second quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock worth $75,000 after acquiring an additional 2,400 shares during the period. JPMorgan Chase & Co. acquired a new position in GH Research during the 2nd quarter worth approximately $79,000. HRT Financial LP purchased a new position in GH Research in the fourth quarter worth $202,000. Finally, BNP Paribas Financial Markets increased its holdings in shares of GH Research by 165.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 17,010 shares of the company’s stock valued at $207,000 after purchasing an additional 10,600 shares in the last quarter. 56.90% of the stock is owned by hedge funds and other institutional investors.

GH Research Company Profile

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.